VYGR · Voyager Therapeutics, Inc.
$3.00
-0.04 (-1.32%)
At close · Jul 29
Market Cap
$183.68M
Shares
60.42M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-07-13 | — | |
| 8-K | 2026-06-10 | 2026-06-09 | |
| 8-K | 2026-06-01 | — | |
| 8-K | 2026-05-07 | — | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| DEF 14A | 2026-04-28 | 2026-06-09 | |
| 8-K | 2026-04-21 | 2026-04-15 | |
| 8-K | 2026-03-09 | — | |
| 10-K | 2026-03-09 | 2025-12-31 | |
| 8-K | 2026-02-12 | 2026-02-09 | |
| 8-K | 2026-01-08 | — | |
| 8-K | 2025-11-10 | — | |
| 10-Q | 2025-11-10 | 2025-09-30 | |
| 8-K | 2025-09-02 | — | |
| 10-Q | 2025-08-06 | 2025-06-30 | |
| 8-K | 2025-08-06 | — | |
| 8-K | 2025-06-05 | 2025-06-03 | |
| 8-K | 2025-05-06 | — | |
| 10-Q | 2025-05-06 | 2025-03-31 | |
| DEF 14A | 2025-04-23 | 2025-06-03 | |
| 8-K | 2025-03-11 | — | |
| 10-K | 2025-03-11 | 2024-12-31 | |
| 8-K | 2025-02-11 | — | |
| 10-Q | 2024-11-12 | 2024-09-30 | |
| 8-K | 2024-11-12 | — | |
| 8-K | 2024-09-05 | 2024-09-03 | |
| 8-K | 2024-08-06 | — | |
| 10-Q | 2024-08-06 | 2024-06-30 | |
| 8-K | 2024-06-13 | 2024-06-11 | |
| 8-K | 2024-06-06 | 2024-06-05 | |
| 8-K | 2024-05-16 | — | |
| 8-K | 2024-05-13 | — | |
| 10-Q | 2024-05-13 | 2024-03-31 | |
| DEF 14A | 2024-04-25 | 2024-06-05 | |
| 8-K | 2024-04-02 | 2024-03-27 | |
| 8-K | 2024-03-13 | 2024-02-29 | |
| 8-K | 2024-02-28 | — | |
| 10-K | 2024-02-28 | 2023-12-31 | |
| 8-K | 2024-01-08 | 2024-01-03 | |
| 8-K | 2024-01-02 | 2023-12-28 | |
| 8-K | 2023-12-06 | — | |
| 8-K | 2023-11-06 | — | |
| 10-Q | 2023-11-06 | 2023-09-30 | |
| 8-K | 2023-08-16 | 2023-08-11 | |
| 8-K | 2023-08-03 | — | |
| 10-Q | 2023-08-03 | 2023-06-30 | |
| 8-K | 2023-07-10 | 2023-07-05 | |
| 8-K | 2023-06-07 | 2023-06-06 | |
| 8-K | 2023-05-09 | — | |
| 8-K | 2023-05-09 | 2023-05-06 |
Showing 1–50 of 105 filings
Key facts
CIK
1640266
CUSIP
92915B106
13F (30d)
25 filings
25 filers
Visit website
Investor relations